• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5050410)   Today's Articles (2397)
For: Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 2024;35:77-90. [PMID: 37879444 DOI: 10.1016/j.annonc.2023.10.117] [Citation(s) in RCA: 131] [Impact Index Per Article: 131.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 10/11/2023] [Accepted: 10/12/2023] [Indexed: 10/27/2023]  Open
Number Cited by Other Article(s)
1
Carlisle JW, Wolner Z, Pannu S, Mitchell C, Hsu M, Aijaz A, Johnson M, Naqash AR. Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration. Am Soc Clin Oncol Educ Book 2025;45:e472792. [PMID: 40397846 DOI: 10.1200/edbk-25-472792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/23/2025]
2
Guidi L, Etessami J, Valenza C, Valdivia A, Meric-Bernstam F, Felip E, Curigliano G. Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances. Am Soc Clin Oncol Educ Book 2025;45:e473148. [PMID: 40198874 DOI: 10.1200/edbk-25-473148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/10/2025]
3
Le X, Eisert A, Hsia TC, Raut NV, Ahmad A, Chan OSH, De Bondt C, Farrugia D, Froesch P, González-Cao M, Hendriks L, Hochmair MJ, Mazieres J, O'Sullivan H, Popat S, Samol J, van der Wekken AJ, Yang TY, Tho LM, Himpe U, Lam WS, Lee KWC, Petrini I, Berghoff K, Karachaliou N, Joshi K, Vlassak S, Chang GC. Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series. Clin Lung Cancer 2025;26:338-346.e1. [PMID: 40140342 DOI: 10.1016/j.cllc.2025.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2024] [Revised: 02/18/2025] [Accepted: 02/18/2025] [Indexed: 03/28/2025]
4
Waissengrin B, Reckamp KL. An evaluation of patritumab deruxtecan for the treatment of EGFR-mutated non-small cell lung cancer. Expert Opin Biol Ther 2025:1-9. [PMID: 40374579 DOI: 10.1080/14712598.2025.2507833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2025] [Revised: 04/28/2025] [Accepted: 05/14/2025] [Indexed: 05/17/2025]
5
Zhang W, Xiong J, Li Y, Nie J, Zhao W, Guo Z, Liu X, Zhang Q, Chen X, Ye L, Chen Z, Wang H, Xu K, Zhao L, Liu Y, Huang L, Li Y, He Y. Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis. Ther Adv Med Oncol 2025;17:17588359251338046. [PMID: 40396122 PMCID: PMC12089717 DOI: 10.1177/17588359251338046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2025] [Accepted: 04/08/2025] [Indexed: 05/22/2025]  Open
6
Adou M, Guisier F. [Amivantamab with lazertinib - stage IV non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation]. Bull Cancer 2025:S0007-4551(25)00200-0. [PMID: 40379500 DOI: 10.1016/j.bulcan.2025.02.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2025] [Accepted: 02/16/2025] [Indexed: 05/19/2025]
7
Kawauchi D, Narita Y. The curse of blood-brain barrier and blood-tumor barrier in malignant brain tumor treatment. Int J Clin Oncol 2025:10.1007/s10147-025-02777-3. [PMID: 40338447 DOI: 10.1007/s10147-025-02777-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2025] [Accepted: 04/24/2025] [Indexed: 05/09/2025]
8
Miyata M, Hayashi H. Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations. Respir Investig 2025;63:576-584. [PMID: 40328075 DOI: 10.1016/j.resinv.2025.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2025] [Revised: 04/14/2025] [Accepted: 04/22/2025] [Indexed: 05/08/2025]
9
Kannan K, Mohan S. Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs. Med Oncol 2025;42:196. [PMID: 40325239 DOI: 10.1007/s12032-025-02755-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2025] [Accepted: 04/28/2025] [Indexed: 05/07/2025]
10
Gomez-Randulfe I, Monaca F, Planchard D, Bria E, Califano R. Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations. Crit Rev Oncol Hematol 2025;212:104762. [PMID: 40324662 DOI: 10.1016/j.critrevonc.2025.104762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2025] [Revised: 04/26/2025] [Accepted: 05/01/2025] [Indexed: 05/07/2025]  Open
11
Han L, Wang K, Jiang Z, Guo X, Yu J. Recent development in bispecific antibody immunotherapy for hematological malignancies. Crit Rev Oncol Hematol 2025;212:104752. [PMID: 40320222 DOI: 10.1016/j.critrevonc.2025.104752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2025] [Revised: 04/24/2025] [Accepted: 04/26/2025] [Indexed: 05/08/2025]  Open
12
Chen MF, Jeng MY, Ma J, Agrawal P, Dunne E, Boe LA, Kris MG, Huang J, Veeraraghavan H, Gomez D, Yu HA. Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precis Oncol 2025;9:e2500047. [PMID: 40373257 DOI: 10.1200/po-25-00047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 02/21/2025] [Accepted: 04/07/2025] [Indexed: 05/17/2025]  Open
13
Kim MH, Lee MK, Park JE, Park SH, Jang TW, Jung CY, Kim I, Yoon SH, Ahn JH, Lee HK, Park JH, Choi SH, Eom JS. Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR-Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study. Thorac Cancer 2025;16:e70083. [PMID: 40396522 DOI: 10.1111/1759-7714.70083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2025] [Revised: 04/14/2025] [Accepted: 04/27/2025] [Indexed: 05/22/2025]  Open
14
Sun L, Marmarelis ME, Aggarwal C. Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer. J Clin Oncol 2025;43:1527-1533. [PMID: 40053885 DOI: 10.1200/jco-24-02624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2024] [Revised: 01/27/2025] [Accepted: 02/06/2025] [Indexed: 03/09/2025]  Open
15
Remon J, Saw SPL. Telisotuzumab vedotin and osimertinib: the METamorphosis of epidermal growth factor receptor-mutant lung cancer? Ann Oncol 2025;36:484-487. [PMID: 39855428 DOI: 10.1016/j.annonc.2025.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2025] [Accepted: 01/16/2025] [Indexed: 01/27/2025]  Open
16
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol 2025;36:583-591. [PMID: 39805351 DOI: 10.1016/j.annonc.2025.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2024] [Revised: 12/20/2024] [Accepted: 01/02/2025] [Indexed: 01/16/2025]  Open
17
Pilotto S, Singh PK. Further-Line Treatment With Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC: New Answers to Old Questions? J Thorac Oncol 2025;20:549-554. [PMID: 40348479 DOI: 10.1016/j.jtho.2025.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2025] [Accepted: 02/10/2025] [Indexed: 05/14/2025]
18
Zhou X, Zeng L, Huang Z, Ruan Z, Yan H, Zou C, Xu S, Zhang Y. Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges. Cancer Med 2025;14:e70921. [PMID: 40322930 PMCID: PMC12051098 DOI: 10.1002/cam4.70921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2025] [Accepted: 04/16/2025] [Indexed: 05/08/2025]  Open
19
Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC. CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression. Clin Lung Cancer 2025;26:e214-e222.e5. [PMID: 39933981 DOI: 10.1016/j.cllc.2025.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2024] [Accepted: 01/09/2025] [Indexed: 02/13/2025]
20
Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JCH, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A. J Thorac Oncol 2025;20:651-664. [PMID: 39755170 DOI: 10.1016/j.jtho.2024.12.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2024] [Revised: 12/20/2024] [Accepted: 12/28/2024] [Indexed: 01/06/2025]
21
Barbe-Richaud JB, Fattori A, Lindner V, Schuster C, Malouf G, Pencreach E, Somme L. EGFR-Mutant Urothelial Carcinoma Harboring an Ala750_Ile759delinsGlyGly Alteration with a Primary Resistance to Polychemotherapy and a Sensitivity to Osimertinib: A Literature Review on EGFR Alterations and Response to EGFR Tyrosine Kinase Inhibitors in Cancers. J Clin Med 2025;14:3129. [PMID: 40364160 PMCID: PMC12072851 DOI: 10.3390/jcm14093129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2025] [Revised: 04/20/2025] [Accepted: 04/26/2025] [Indexed: 05/15/2025]  Open
22
Stanzione B, Del Conte A, Bertoli E, De Carlo E, Bortolot M, Torresan S, Spina M, Bearz A. Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies. Cancers (Basel) 2025;17:1515. [PMID: 40361442 PMCID: PMC12071048 DOI: 10.3390/cancers17091515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2025] [Revised: 04/23/2025] [Accepted: 04/26/2025] [Indexed: 05/15/2025]  Open
23
Yan Y, Yuan J, Peng Y, Zhou C, Liu X, Sun L, Song Q. Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward? Front Immunol 2025;16:1568724. [PMID: 40352940 PMCID: PMC12061958 DOI: 10.3389/fimmu.2025.1568724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2025] [Accepted: 04/03/2025] [Indexed: 05/14/2025]  Open
24
Raez LE, Baca Y, Ribeiro JR, Nieva JJ, Mamdani H, Lopes G, Borghaei H, Socinski M, Wozniak AJ, Vanderwalde A, Uribe CC, Sumarriva D, Khan H, Liu SV, Nagasaka M. Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC). Expert Rev Anticancer Ther 2025:1-8. [PMID: 40237370 DOI: 10.1080/14737140.2025.2491648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2025] [Accepted: 04/05/2025] [Indexed: 04/18/2025]
25
Zieliński P, Stępień M, Chowaniec H, Kalyta K, Czerniak J, Borowczyk M, Dwojak E, Mroczek M, Dworacki G, Ślubowska A, Markiewicz H, Ałtyn R, Dobosz P. Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach. Cells 2025;14:587. [PMID: 40277912 PMCID: PMC12026305 DOI: 10.3390/cells14080587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2025] [Revised: 04/07/2025] [Accepted: 04/09/2025] [Indexed: 04/26/2025]  Open
26
Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KKS, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review. J Thorac Oncol 2025;20:465-474. [PMID: 39622411 DOI: 10.1016/j.jtho.2024.11.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2024] [Revised: 11/05/2024] [Accepted: 11/27/2024] [Indexed: 01/12/2025]
27
Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Pérol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol 2025;43:1254-1265. [PMID: 39761483 PMCID: PMC11949215 DOI: 10.1200/jco-24-01349] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Revised: 09/05/2024] [Accepted: 11/14/2024] [Indexed: 03/29/2025]  Open
28
Ou HT, Tsai JH, Chen YL, Wu TI, Chen LJ, Yang SC. Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma. PHARMACOECONOMICS 2025;43:429-440. [PMID: 39752129 DOI: 10.1007/s40273-024-01462-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/01/2024] [Indexed: 01/04/2025]
29
Lan Y, Sun J, Xu J, Chen X. Anti-lung cancer activity of lotusine in non-small cell lung cancer HCC827 via reducing proliferation, oxidative stress, induction of apoptosis, and G0/G1 cell cycle arrest via suppressing EGFR-Akt-ERK signalling. In Vitro Cell Dev Biol Anim 2025;61:450-458. [PMID: 40392483 DOI: 10.1007/s11626-025-01048-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2025] [Accepted: 04/10/2025] [Indexed: 05/22/2025]
30
Soo RA, Vervita K, Früh M, Cho BC, Majem M, Rodriguez Abreu D, Ribi K, Callejo A, Moran T, Domine Gomez M, Provencio M, Addeo A, Han JY, Ortega Granados AL, Reck M, Blasco A, Garcia Campelo R, Sala González MA, Britschgi C, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Haberecker M, Dafni U, Peters S, Stahel RA. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. Lung Cancer 2025;202:108454. [PMID: 40023017 DOI: 10.1016/j.lungcan.2025.108454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2024] [Revised: 01/29/2025] [Accepted: 02/16/2025] [Indexed: 03/04/2025]
31
Khan SR, Breadner D. Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment. Curr Oncol 2025;32:206. [PMID: 40277763 PMCID: PMC12025875 DOI: 10.3390/curroncol32040206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2025] [Revised: 03/23/2025] [Accepted: 03/27/2025] [Indexed: 04/26/2025]  Open
32
Romaniello D, Morselli A, Marrocco I. Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer. Int J Mol Sci 2025;26:2957. [PMID: 40243603 PMCID: PMC11988377 DOI: 10.3390/ijms26072957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2025] [Revised: 03/22/2025] [Accepted: 03/23/2025] [Indexed: 04/18/2025]  Open
33
Byeon H. Enhancing recovery in non-small cell lung cancer patients through mindfulness training and Jinshui Liujun decoction supplementation. World J Psychiatry 2025;15:101876. [PMID: 40110006 PMCID: PMC11886325 DOI: 10.5498/wjp.v15.i3.101876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2024] [Revised: 01/03/2025] [Accepted: 01/11/2025] [Indexed: 02/26/2025]  Open
34
Patel KB, Heppner DE. Lazertinib: breaking the mold of third-generation EGFR inhibitors. RSC Med Chem 2025;16:1049-1066. [PMID: 39867588 PMCID: PMC11758113 DOI: 10.1039/d4md00800f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2024] [Accepted: 01/02/2025] [Indexed: 01/28/2025]  Open
35
Sattler M, Salgia R. The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. Cell Rep Med 2025;6:101983. [PMID: 40020676 PMCID: PMC11970332 DOI: 10.1016/j.xcrm.2025.101983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Revised: 01/27/2025] [Accepted: 01/31/2025] [Indexed: 03/03/2025]
36
Kim J, Park S, Ku BM, Ahn MJ. Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer. Cancer 2025;131 Suppl 1:e35778. [PMID: 40171939 DOI: 10.1002/cncr.35778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Revised: 08/28/2024] [Accepted: 09/30/2024] [Indexed: 04/04/2025]
37
Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JCH, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S. Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset. Lung Cancer 2025;204:108496. [PMID: 40300278 DOI: 10.1016/j.lungcan.2025.108496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2025] [Accepted: 03/14/2025] [Indexed: 05/01/2025]
38
Bouchard N, Daaboul N. Lung Cancer: Targeted Therapy in 2025. Curr Oncol 2025;32:146. [PMID: 40136350 PMCID: PMC11941068 DOI: 10.3390/curroncol32030146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2025] [Revised: 02/23/2025] [Accepted: 02/26/2025] [Indexed: 03/27/2025]  Open
39
Czogalla M, Stöhr J, Gleim N, Papsdorf K, Klagges S, Hambsch P, Kuhnt T, Nägler F, Barrantes-Freer A, Wach J, Nicolay N, Seidel C. Short-term survivors with brain metastases have modest benefits from focal and systemic therapies and remain frequent despite improving treatment landscape. Clin Transl Radiat Oncol 2025;51:100919. [PMID: 39877301 PMCID: PMC11772985 DOI: 10.1016/j.ctro.2025.100919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2024] [Revised: 12/22/2024] [Accepted: 01/09/2025] [Indexed: 01/31/2025]  Open
40
Brazel D, Smith J, Ou SHI, Nagasaka M. The User's Guide to Amivantamab. Target Oncol 2025;20:235-245. [PMID: 39903428 PMCID: PMC11933153 DOI: 10.1007/s11523-025-01128-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/20/2025] [Indexed: 02/06/2025]
41
Lefèvre A, Besse B. [Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression]. Bull Cancer 2025;112:3S75-3S85. [PMID: 40155080 DOI: 10.1016/s0007-4551(25)00160-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/01/2025]
42
Gridelli C, Mok T, Jänne P, Passaro A, Felip E, Ramalingam SS, Attili I, de Marinis F. Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT). Lung Cancer 2025;201:108100. [PMID: 39986216 DOI: 10.1016/j.lungcan.2025.108100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2024] [Revised: 01/15/2025] [Accepted: 01/16/2025] [Indexed: 02/24/2025]
43
Spagnuolo A, Gridelli C. Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer. Expert Opin Pharmacother 2025;26:491-501. [PMID: 39935000 DOI: 10.1080/14656566.2025.2464903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Accepted: 02/05/2025] [Indexed: 02/13/2025]
44
Nishi T, Morita A, Hara N, Makimoto G, Ninomiya K, Fujii M, Rai K, Ohashi K, Hotta K, Tabata M, Togashi Y, Maeda Y, Ichihara E. Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines. Lung Cancer 2025;201:108415. [PMID: 39922174 DOI: 10.1016/j.lungcan.2025.108415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2024] [Revised: 01/21/2025] [Accepted: 01/30/2025] [Indexed: 02/10/2025]
45
Maione P, Palma V, Pucillo G, Gridelli C. New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib. Cancers (Basel) 2025;17:847. [PMID: 40075694 PMCID: PMC11898774 DOI: 10.3390/cancers17050847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 02/22/2025] [Accepted: 02/27/2025] [Indexed: 03/14/2025]  Open
46
Ramos R, Moura CS, Costa M, Lamas NJ, Correia R, Garcez D, Pereira JM, Lindahl T, Sousa C, Vale N. Lung Cancer Therapy: The Role of Personalized Medicine. Cancers (Basel) 2025;17:725. [PMID: 40075573 PMCID: PMC11899562 DOI: 10.3390/cancers17050725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2024] [Revised: 02/18/2025] [Accepted: 02/19/2025] [Indexed: 03/14/2025]  Open
47
Hasan N, Nagasaka M. Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer. Expert Rev Respir Med 2025:1-10. [PMID: 39965618 DOI: 10.1080/17476348.2025.2467338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Revised: 01/18/2025] [Accepted: 02/11/2025] [Indexed: 02/20/2025]
48
Lim JU, Jung J, Kim YW, Kim CY, Lee SH, Park DW, Choi SI, Ji W, Yeo CD, Lee SH. Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges. Biomedicines 2025;13:470. [PMID: 40002883 PMCID: PMC11852785 DOI: 10.3390/biomedicines13020470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Revised: 02/11/2025] [Accepted: 02/13/2025] [Indexed: 02/27/2025]  Open
49
Nicoś M, Sroka-Bartnicka A, Kalinka E, Krawczyk P. Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene. Cancers (Basel) 2025;17:563. [PMID: 40002158 PMCID: PMC11852969 DOI: 10.3390/cancers17040563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Revised: 02/04/2025] [Accepted: 02/05/2025] [Indexed: 02/27/2025]  Open
50
Zhang J, Li W. Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. BMC Pulm Med 2025;25:63. [PMID: 39915804 PMCID: PMC11800505 DOI: 10.1186/s12890-025-03509-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2024] [Accepted: 01/20/2025] [Indexed: 02/11/2025]  Open
PrevPage 1 of 3 123Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel